522 related articles for article (PubMed ID: 9393627)
61. [Interleukin-12 restores and promotes the T-cell immune function inhibited by 5-fluorouracil].
Chi PD; Li L; Fan YY; Wu CY
Ai Zheng; 2007 Aug; 26(8):801-8. PubMed ID: 17697537
[TBL] [Abstract][Full Text] [Related]
62. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
63. Effects of Korean mistletoe lectin (Viscum album coloratum) on proliferation and cytokine expression in human peripheral blood mononuclear cells and T-lymphocytes.
Lyu SY; Park WB
Arch Pharm Res; 2007 Oct; 30(10):1252-64. PubMed ID: 18038904
[TBL] [Abstract][Full Text] [Related]
64. Kinetics of cytokine and NFAT gene expression in human interleukin-2-dependent T lymphoblasts stimulated via T-cell receptor.
Sareneva T; Matikainen S; Vanhatalo J; Melén K; Pelkonen J; Julkunen I
Immunology; 1998 Mar; 93(3):350-7. PubMed ID: 9640245
[TBL] [Abstract][Full Text] [Related]
65. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.
Kroesen BJ; Buter J; Sleijfer DT; Janssen RA; van der Graaf WT; The TH; de Leij L; Mulder NH
Br J Cancer; 1994 Oct; 70(4):652-61. PubMed ID: 7917912
[TBL] [Abstract][Full Text] [Related]
66. FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells.
Sakuma S; Kato Y; Nishigaki F; Sasakawa T; Magari K; Miyata S; Ohkubo Y; Goto T
Br J Pharmacol; 2000 Aug; 130(7):1655-63. PubMed ID: 10928971
[TBL] [Abstract][Full Text] [Related]
67. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.
Hoffmann P; Hofmeister R; Brischwein K; Brandl C; Crommer S; Bargou R; Itin C; Prang N; Baeuerle PA
Int J Cancer; 2005 May; 115(1):98-104. PubMed ID: 15688411
[TBL] [Abstract][Full Text] [Related]
68. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
Tutt A; Stevenson GT; Glennie MJ
J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
[TBL] [Abstract][Full Text] [Related]
69. T Cell-Activating Bispecific Antibodies in Cancer Therapy.
Trabolsi A; Arumov A; Schatz JH
J Immunol; 2019 Aug; 203(3):585-592. PubMed ID: 31332079
[TBL] [Abstract][Full Text] [Related]
70. Heterodimeric complex formation with CD8 and TCR by bispecific antibody sustains paracrine IL-2-dependent growth of CD3+ CD8+ T cells.
De Lau WB; Boom SE; Heije K; Griffioen AW; Braakman E; Bolhuis RL; Tax WJ; Clevers H; Bast BJ
J Immunol; 1992 Sep; 149(6):1840-6. PubMed ID: 1387662
[TBL] [Abstract][Full Text] [Related]
71. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
Trinklein ND; Pham D; Schellenberger U; Buelow B; Boudreau A; Choudhry P; Clarke SC; Dang K; Harris KE; Iyer S; Jorgensen B; Pratap PP; Rangaswamy US; Ugamraj HS; Vafa O; Wiita AP; van Schooten W; Buelow R; Force Aldred S
MAbs; 2019; 11(4):639-652. PubMed ID: 30698484
[TBL] [Abstract][Full Text] [Related]
72. T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent.
Gruen M; Bommert K; Bargou RC
Cancer Immunol Immunother; 2004 Jul; 53(7):625-32. PubMed ID: 15175907
[TBL] [Abstract][Full Text] [Related]
73. Stimulation of human peripheral blood mononuclear cells with anti-CD3 monoclonal antibody vs IL2: disparate effects on T cell-dependent B cell differentiation despite similar effects on generation of unrestricted cytolytic activity.
Stohl W; Elliott JE
Clin Immunol Immunopathol; 1992 Oct; 65(1):30-8. PubMed ID: 1395122
[TBL] [Abstract][Full Text] [Related]
74. T-cell activation induced by anti-CD3 x anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand.
Wooldridge JE; Dahle CE; Weiner GJ
Cancer Immunol Immunother; 1997; 45(3-4):174-9. PubMed ID: 9435867
[TBL] [Abstract][Full Text] [Related]
75. Triggered human mucosal T cells release tumour necrosis factor-alpha and interferon-gamma which kill human colonic epithelial cells.
Deem RL; Shanahan F; Targan SR
Clin Exp Immunol; 1991 Jan; 83(1):79-84. PubMed ID: 1899066
[TBL] [Abstract][Full Text] [Related]
76. Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model.
Panjideh H; Müller G; Koch M; Wilde F; Scheu S; Moldenhauer G; Lipp M
Int J Cancer; 2014 Dec; 135(11):2623-32. PubMed ID: 24729415
[TBL] [Abstract][Full Text] [Related]
77. Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28-mediated costimulation is accompanied by Th1 differentiation and recruitment of MHC-independent cytotoxicity.
Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
Clin Exp Immunol; 1997 May; 108(2):352-7. PubMed ID: 9158110
[TBL] [Abstract][Full Text] [Related]
78. OKT3 F(ab')2 fragments--retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release.
Woodle ES; Thistlethwaite JR; Ghobrial IA; Jolliffe LK; Stuart FP; Bluestone JA
Transplantation; 1991 Aug; 52(2):354-60. PubMed ID: 1908148
[TBL] [Abstract][Full Text] [Related]
79. Down-regulation of lymphokine synthesis by intravenous gammaglobulin is dependent upon accessory cells.
Skansén-Saphir U; Andersson J; Björk L; Ekberg C; Fehniger TE; Henter JI; Andersson U
Scand J Immunol; 1998 Mar; 47(3):229-35. PubMed ID: 9519861
[TBL] [Abstract][Full Text] [Related]
80. Bispecific antibody-mediated cytotoxicity by CD4+ and CD8(+)-activated T cells generated from leukemia patients after allogeneic bone marrow transplantation.
Hattori K; Tsukamoto H; Ohta S; Yabe M; Yabe H; Kato S; Takakura I; Ueda R; Habu S; Nishimura T
Bone Marrow Transplant; 1995 Feb; 15(2):193-8. PubMed ID: 7773208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
